Date: 2015-06-15
Type of information: Licensing agreement
Compound: KODE™ Technology
Company: Agalimmune (UK) KODE Biotech (New Zealand)
Therapeutic area: Cancer - Oncology - Technology - Services
Type agreement: licensing
Action mechanism: KODE™ technology provides a platform for rapid modification of virtually any surface with any functional molecule.
Disease:
Details: * On June 15, 2015, Agalimmune, a biopharmaceutical company focused on the development of a pipeline of innovative immunotherapies for the personalised treatment of cancer, announced it has licensed KODE Biotech’s Function-Spacer-Lipid (FSL) cell surface membrane modification technology (KODE™ Technology). The proprietary technology will be incorporated by Agalimmune into its novel cancer immunotherapy molecules. KODE™ Technology has been extensively validated by Agalimmune prior to in-licensing, and has been shown to be effective for treatment of both primary and secondary tumours in animal models. Agalimmune injects synthetic animal-antigen mimetics, which incorporate the FSL constructs, into primary tumours. As the immune system naturally rejects animal tissue, it attacks the modified tumour. In this process of destroying the tumour, the body’s immune system is educated to recognise the patient’s own (autologous) tumour antigens and so destroy unmodified primary and secondary tumours. KODE™ constructs have been engineered to be easily dispersed in biocompatible media, spontaneously incorporate into cell membranes, and have low toxicity.
Financial terms: Under the terms of the agreement, KODE may receive up to $31 million USD (£21 million GBP) in development and sales milestones, plus royalties on net sales. Agalimmune has exclusive rights to the use of the technology in the field of intratumoral injection for cancer treatment, and specifically relating to the clinical candidate molecule AGI-134.
Latest news:
